A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India

The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).

Start Date18 Apr 2024

Sponsor / Collaborator

Eli Lilly & Co.

[+1]

NCT06674135 / CompletedPhase 4IIT

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh

Start Date01 Jun 2022

Sponsor / Collaborator

Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders

[+1]

NCT06624943 / CompletedPhase 4IIT

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Mali

This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe.

Start Date14 Mar 2022

Sponsor / Collaborator

Centre Hospitalier de Luxembourg

[+1]

100 Clinical Results associated with Insulin Glargine(Boehringer Ingelheim)

100 Translational Medicine associated with Insulin Glargine(Boehringer Ingelheim)

100 Patents (Medical) associated with Insulin Glargine(Boehringer Ingelheim)

Literatures (Medical) associated with Insulin Glargine(Boehringer Ingelheim)

01 Jul 2023·Journal of managed care & specialty pharmacy

Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States.

Article

Author: McDermott, Cara L ; Marshall, James ; Toh, Sengwee ; Nam, Young Hee ; Mendelsohn, Aaron B ; Lockhart, Catherine M ; Rai, Ashish

BACKGROUND: The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM), was approved in 2015 in the United States. Information on the uptake, user characteristics, and outcomes of follow-on insulin remains sparse. OBJECTIVE: To describe the utilization, user characteristics, and health outcomes of the follow-on insulin glargine and insulin glargine originators in a large, distributed network of primarily commercially insured patients in the United States. METHODS: We used health care claims data in the US Food and Drug Administration's Sentinel common data model format across 5 research partners in the Biologics & Biosimilars Collective Intelligence Consortium distributed research network. Sentinel analytic tools were used to identify adult users of insulin glargine between January 1, 2011, and February 28, 2021, and describe patient demographics, baseline clinical characteristics, and adverse health events among users of the originators and the follow-on drug, stratified by diabetes type. RESULTS: We identified 508,438 users of originator drugs and 63,199 users of the follow-on drug. The proportions of the follow-on drug users among total insulin glargine users were 9.1% (n = 7,070) for T1DM and 11.4% (n=56,129) for T2DM. Follow-on use rose from 8.2% in 2017 to 24.8% in 2020, accompanied by a steady decrease in the use of originator drugs. Demographics of the users of the originators and follow-on drug were similar among the T1DM and T2DM groups. Overall, follow-on users had poorer baseline health profile and higher proportions of episodes with adverse events in the follow-up. CONCLUSIONS: We found evidence of increased uptake of the follow-on drug relative to the originator products in the post-2016 period. The differences in the base-line clinical characteristics between users of the originator products and the follow-on drug and their relationship with health outcomes merit further research. DISCLOSURES: Sengwee Toh consults for Pfizer, Inc., and TriNetX, LLC. This study was funded by the BBCIC.

02 Jun 2023·JAMA health forum

Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019.

Article

Author: Hernandez, Inmaculada ; Gabriel, Nico ; Dickson, Sean ; Gellad, Walid F

ImportanceDespite the political salience of insulin prices, no study to date has quantified trends in insulin prices that account for manufacturer discounts (net prices).ObjectiveTo describe trends in insulin list prices and net prices faced by payers from 2012 to 2019 and estimate changes in net prices after the 2015 to 2017 entry of new insulin products.Design, Setting, and ParticipantsThis longitudinal study included an analysis of Medicare, Medicaid, and SSR Health drug pricing data from January 1, 2012, to December 31, 2019. Data analyses were performed from June 1, 2022, to October 31, 2022.ExposuresUS sales of insulin products.Main Outcomes and MeasuresNet prices faced by payers were estimated for insulin products as list prices minus manufacturer discounts negotiated in commercial and Medicare Part D markets (ie, commercial discounts). Trends in net prices were evaluated before and after the entry of new insulin products.ResultsNet prices of long-acting insulin products increased at an annual rate of 23.6% from 2012 to 2014 but decreased at an annual rate of 8.3% after the introduction of insulin glargine (Toujeo and Basaglar) and degludec (Tresiba) in 2015. Net prices of short-acting insulin increased at an annual rate of 5.6% from 2012 to 2017 but then decreased from 2018 to 2019 after the introduction of insulin aspart (Fiasp) and lispro (Admelog). For human insulin products, which did not experience entry of new products, net prices increased at an annual rate of 9.2% from 2012 to 2019. From 2012 to 2019, commercial discounts increased from 22.7% to 64.8% for long-acting insulin products, from 37.9% to 66.1% for short-acting insulin products, and from 54.9% to 63.1% for human insulin products.Conclusions and RelevanceIn this longitudinal study of US insulin products, results suggest that insulin prices substantially increased from 2012 to 2015, even after accounting for discounts. The introduction of new insulin products was followed by substantial discounting practices that lowered net prices faced by payers.

03 Apr 2023·The Medical letter on drugs and therapeutics

In Brief: Rezvoglar - another insulin glargine product interchangeable with Lantus.

Article

News (Medical) associated with Insulin Glargine(Boehringer Ingelheim)

30 Sep 2024

·www.globenewswire.com

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association’s 84th Scientific SessionsSwitching to, or remaining on Afrezza allowed twice as many people to get to goal during the extension phase DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups – one that utilized Afrezza® (plus basal insulin) over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections (MDI), an automated insulin delivery system, (AID) or a pump without automation. “The data from the extension phase of this study showed that more people living with T1D are able to reach target A1c levels when they remain on Afrezza (plus basal insulin) or switch to Afrezza from usual care – whether they are using multiple daily injections or pumps,” said Michael Castagna, PharmD, Chief Executive Officer for MannKind Corporation. “We believe this data demonstrates to healthcare practitioners that Afrezza is an effective tool for their patients who want to improve their glycemic control.” Key Findings:There was continued improvement in the Afrezza (plus degludec)-treated group, with additional subjects achieving A1c <7% at 30 weeks – a 100% increase from baseline: Switching from usual care to Afrezza (plus degludec) at week-17 allowed more than double the subjects to achieve A1c <7% at week-30, compared to the number at goal at week-17: “With the positive data received at both 17- and 30-weeks, we continue to affirm that Afrezza is an important option for adult patients managing their diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. “We look forward to discussing more details of the 30-week study results at ATTD next March and additional conferences in 2025.” About the INHALE-3 StudyThe INHALE-3 study is a 17-week, randomized controlled trial with a 13-week extension conducted across 19 U.S. sites. The study, which enrolled 141 patients (123 randomized), assigned participants over 18 years of age with T1D who are using MDI, an automated insulin delivery system, or a pump without automation to either continue their standard of care or initiate an insulin regimen of a daily basal injection plus Afrezza for boluses (mealtime and corrections). Subjects utilizing Afrezza (inhaled insulin) received a higher initial conversion dose than in the current U.S. product label. Both arms utilized continuous glucose monitoring to assess glucose control. The randomized control trial (RCT) included an inhaled insulin group that began with 62 subjects at randomization and 57 at 17 weeks; the usual care group consisted of 61subjects at randomization and 58 at 17 weeks. The 17-week results previously shared that the study met its primary efficacy endpoint of a non-inferior change in HbA1c between baseline and week 17 compared to the usual care group. At 17 weeks, those who utilized Afrezza (plus basal insulin) continued with it through the extension phase, and those who were on usual care switched over to Afrezza to week 30. The extension phase started with 45 subjects from the inhaled insulin group and 43 completed the extension; the usual care-to-Afrezza group started with 49 in the extension, with 42 completing. There was no control group in the extension phase. A1c levels were obtained at baseline, 17 and 30-weeks. More information on the INHALE-3 study is available at: ClinicalTrials.gov(NCT05904743). About AfrezzaAfrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking. Important Safety Information WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE Acute bronchospasm has been observed in Afrezza-treated patients with asthma and COPDAfrezza is contraindicated in patients with chronic lung disease such as asthma or COPDBefore initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation. Please see additional Important Safety Information, Full Prescribing Information, including BOXED WARNING, available on Afrezza.com/safety. About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking Statements [to be updated as necessary]This press release contains forward-looking statements about the planned release of results from a clinical study that involves risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that we may not achieve our projected development goals in the timeframes we expect as well as other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/31d76640-1047-4108-b133-36b48e91775d https://www.globenewswire.com/NewsRoom/AttachmentNg/650dc7f2-1e72-487b-9047-d0fdce0a795f https://www.globenewswire.com/NewsRoom/AttachmentNg/040e275d-bd09-4b8c-abff-4b7d76b32321 https://www.globenewswire.com/NewsRoom/AttachmentNg/72bbb5f4-f42f-4a1e-9121-3d4ff8c57790 This press release was published by a CLEAR® Verified individual.

Clinical ResultPhase 3

27 Sep 2024

·endpts.com

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Novo Nordisk has told government and global nonprofits that it plans to significantly downsize its manufacturing of some of its insulin pens, according to one of the groups, and will transition a portion of its global supply to insulin vials and syringes that are easier to make but less convenient for patients. The company’s plans were disclosed in recent discussions with Doctors Without Borders, who described them to Endpoints News , as well as the WHO, the Australian government, and other governments and regulators. “We are not halting production of insulin in pens,” Novo said in an email to Endpoints. “In some cases, we will no longer make human insulin available in pens. It will be made available in a vial and disposable syringe.” While some countries, like Australia and South Africa, are now seeking alternatives, the full extent of Novo’s plans isn’t immediately clear. The company declined to comment further to Endpoints on exactly which markets would be affected. And it said that some — but not all — insulin pens would be affected by the shift. And it emphasized that the changes would happen slowly, over a period of years. While South Africa in June announced shortages of insulin pens due to Novo’s decision to deprioritize their manufacture and supply, Doctors Without Borders’ pharmacist coordinator Christina Cepuch told Endpoints Friday that the latest announcement would go much further, based on the company’s comments to the groups. Geneva-based Doctors Without Borders is also known as Médecins Sans Frontières, or MSF. The WHO lists Novo’s insulin pens on its essential medicines list , and will also have to find alternatives, Cepuch said. The WHO did not immediately respond to a request for comment. “What does the WHO do about this? There’s not going to be any left. I mean, Lilly makes these, but they don’t make large volumes,” Cepuch said. “And what is WHO going to tell member states? Change everyone to glargine pens or go back to vials?” Glargine is a form of long-acting insulin, and Novo is currently in the process of phasing out its own long-acting insulin, called Levemir. On Tuesday, the Therapeutic Goods Administration, Australia’s drug regulator, released a short notice saying Novo will discontinue “some of its earlier generation insulin products” over the next two years. Scant on details, the notice said Australia is looking into alternatives. Novo emphasized to Endpoints that it is expanding its overall drug manufacturing significantly with the acquisition of Catalent and other new investments. Earlier this week, the Danish company’s CEO Lars Fruergaard Jørgensen testified before the US Senate at a hearing on drug prices and was asked by Sen. Tammy Baldwin (D-WI) about its insulin manufacturing plans. Baldwin asked Jørgensen if he would commit to “continue to have a focus on providing critical insulin. You will not reduce your manufacturing capacity in that area.” “The world market for insulin is actually declining, so there’s less demand,” Jørgensen responded. “But we are committed to supply to the patient that has been using our insulin for years also into the future.” Cepuch suggested that the company might decide to use freed-up pen capacity for its GLP-1 obesity products, which are also in shortage, or other insulins. Novo said the insulin and GLP-1 pens are different.

11 Sep 2024

·www.drugs.com

Weekly Insulin Injections As Effective for Diabetes as Daily Shots, Studies Show

WEDNESDAY, Sept. 11, 2024 -- Weekly insulin shots can help control both type 1 and type 2 diabetes as well as daily injections do, a pair of clinical trials have found. A new class of insulin called efsitora alfa has been designed to require injections only once a week, researchers said. Two phase 3 trials presented Tuesday at the European Association for the Study of Diabetes annual meeting in Madrid show that efsitora is as safe and effective as standard daily insulin shots: “A once-weekly insulin has the potential to simplify dose administration and diminish barriers to starting insulin therapy by means of a reduction in injection burden as compared with a once-daily insulin,” wrote the team behind the type 2 diabetes trial, which was led by Dr. Carol Wysham , an endocrinologist with the MultiCare Rockwood Center for Diabetes and Endocrinology in Spokane, Wash. "Traditionally, basal insulins are dosed once a day -- a treatment schedule that can make compliance difficult for a significant portion of people living with type 2 diabetes," said Wysham said in a news release from drug maker Eli Lily. "Efsitora has the potential to address treatment burden and improve adherence -- all while lowering A1C. These results can make a significant impact for people living with type 2 diabetes looking for a once-weekly option that provides similar outcomes as daily insulins." In both clinical trials, which lasted 52 weeks, researchers randomly assigned participants to taking either efsitora or degludec insulin. The major difference in the results between the two trials involved hypoglycemic (low blood sugar) events. The type 2 diabetes trial found no statistically significant difference between efsitora and degludec when it came to hypoglycemia. But hypoglycemia occurred more often for type 1 diabetics taking efsitora (10%) compared with degludec (3%), results show. More work is needed to figure out the best dose “to maintain efficacy while mitigating the risk of hypoglycemia with weekly efsitora treatment in people with type 1 diabetes,” concluded the type 1 diabetes trial team led by Dr. Richard Bergenstal , executive director of the HealthPartners Institute's International Diabetes Center in Minneapolis. "People with type 1 diabetes need insulin every day. Currently, they can deliver the insulin using an automated insulin delivery system or by taking a daily basal insulin injection and multiple mealtime insulin injections each day," Bergenstal explained in an Eli Lilly news release . "This new data shows that with one dose a week of basal insulin, efsitora was able to achieve a similar A1C reduction as taking an injection of one of the most used background insulins every day. I look forward to further evaluation of these data, including ways to minimize hypoglycemia, so once-weekly insulin can be one option for personalizing the management of type 1 diabetes." The type 2 diabetes trial also found that efsitora worked well in diabetics even if they were taking a GLP-1 drug like Ozempic. “Given treatment guidelines and recommendations to incorporate GLP-1 receptor agonists earlier in treatment, along with their growing use worldwide, it is relevant to show that efsitora can be effectively and safely added to such therapy,” Wysham’s team concluded in a meeting news release. Type 1 diabetes is an inherited condition in which the immune system destroys or damages the body’s ability to make insulin. People with type 2 diabetes develop resistance to insulin, which also can destroy or damage the ability to make insulin. Results from the type 2 diabetes trial were published Sept. 10 in the New England Journal of Medicine , while results from the type 1 trial were published Sept. 10 in The Lancet . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3Clinical ResultPhase 2

100 Deals associated with Insulin Glargine(Boehringer Ingelheim)

External Link

KEGG	Wiki	ATC	Drug Bank
D03250	Insulin Glargine(Boehringer Ingelheim)	A10AE04	DB00047

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	US	Eli Lilly & Co.	16 Dec 2015
Diabetes Mellitus, Type 2	US	Eli Lilly & Co.	16 Dec 2015
Diabetes Mellitus	IS	Eli Lilly Nederland BV	09 Sep 2014
Diabetes Mellitus	LI	Eli Lilly Nederland BV	09 Sep 2014
Diabetes Mellitus	EU	Eli Lilly Nederland BV	09 Sep 2014
Diabetes Mellitus	NO	Eli Lilly Nederland BV	09 Sep 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Phase 3	US	Boehringer Ingelheim GmbH	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	PL	Eli Lilly & Co.	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	BE	Boehringer Ingelheim GmbH	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	GR	Boehringer Ingelheim GmbH	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	BE	Eli Lilly & Co.	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	RO	Eli Lilly & Co.	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	HU	Boehringer Ingelheim GmbH	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	PL	Boehringer Ingelheim GmbH	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	MX	Eli Lilly & Co.	01 Aug 2011
Diabetes Mellitus, Type 1	Phase 3	JP	Boehringer Ingelheim GmbH	01 Aug 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ONWARDS 5 (ADA2023)	Not Applicable	Diabetes Mellitus, Type 2	-	Once-Weekly Insulin Icodec with a Dosing Guide App	iygdfjirec(dkopdxtpwl) = kwyoxmswny agrcvbjhku (nonscnzexh )	Positive	20 Jun 2023
				Once-Daily Basal Insulin Analogs (degludec, glargine U100 or glargine U300)	iygdfjirec(dkopdxtpwl) = tewuzgivqu agrcvbjhku (nonscnzexh )
Simplify study (EASD2022)	Not Applicable	Diabetes Mellitus, Type 2 HbA1c \| insulin secretion \| TDDI	147	Insulin degludec and liraglutide	tlortnovuo(iuyxuwkedl) = nmlaabdmad rkcnrdshid (qlgrymgait, 17.9) View more	Positive	23 Sep 2022
				Basal insulin + prandial insulin boluses	tlortnovuo(iuyxuwkedl) = ggrfzfyazl rkcnrdshid (qlgrymgait, 18.3) View more
ADA2022	Not Applicable	-	-	Insulin Glargine 100 U/mL (Gla-100)	(imjwggscej) = rmnhuqftoh vaybovtkuu (lhqaihbqdi )	Positive	01 Jun 2022
				Insulin Glargine 300 U/mL (Gla-300)	(imjwggscej) = skycwesdnw vaybovtkuu (lhqaihbqdi )
NCT03338023 (Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 1	272	insulin lispro+LY2963016	(qiersmxnsy) = mefdrgkuel uobpqftzjq (zibmwbpwjw, 0.07)	Similar	01 Oct 2021
				insulin lispro+insulin glargine	(qiersmxnsy) = kbgjurwaqs uobpqftzjq (zibmwbpwjw, 0.07)
EASD2021	Not Applicable	Diabetes Mellitus, Type 2	17,643	basal insulin	(dzwnlgelyl) = ljldhpkmhm xsthdvbiaz (ekxsuxmcfi, 6.11 - 6.24) View more	Positive	30 Sep 2021
				basal insulin	(dzwnlgelyl) = tximeagndm xsthdvbiaz (ekxsuxmcfi, 6.63 - 6.71) View more
NCT03338010 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	536	LY2963016	(jyxbxrtdfn) = frrieqxeir mfzrycyvfj (xvvltvnvlb )	Non-inferior	01 Aug 2021
				insulin glargine	(jyxbxrtdfn) = vbytrvcyfc mfzrycyvfj (xvvltvnvlb )
NCT03338010 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	536	LY2963016 (LY2963016)	qrftrxzshj(vcbtwpireq) = obwquowkuf uqxutjpuvc (ukychdcxag, kydhbpphvj - vzinnofwna) View more	-	25 May 2021
				Lantus® (Lantus®)	qrftrxzshj(vcbtwpireq) = qeoumasils uqxutjpuvc (ukychdcxag, yxktvrxmts - jajhvmtgip) View more
NCT03338023 (ABES, CTgov)	Phase 3	Diabetes Mellitus, Type 1	272	LY2963016+Insulin Lispro (LY2963016 + Insulin Lispro)	ndzgzzrgkd(opdzqszmqx) = izekictmql kvhwosamvp (xbapkftzxz, valbwbdcuk - rhnjnjxeic) View more	-	29 Mar 2021
				Lantus®+Insulin Lispro (Lantus® + Insulin Lispro)	ndzgzzrgkd(opdzqszmqx) = daxhoaktne kvhwosamvp (xbapkftzxz, zjdrmbkepl - qkfnimcsid) View more
NCT03555305 (CTgov)	Phase 1	-	58	Insulin Glargine (0.5 U/kg Insulin Glargine)	gctwgzxugz(ctnlgqvmqp) = cmnspghsqn jvmucrwmuw (snxfcdwsfn, egcbvyuvmx - kyhmaqauaa) View more	-	24 Nov 2020
				Lantus (0.5 U/kg Lantus)	gctwgzxugz(ctnlgqvmqp) = awatzinoap jvmucrwmuw (snxfcdwsfn, spmnrsbgch - mneglojlzq) View more
DosInGlar study (EASD2020)	Not Applicable	Diabetes Mellitus, Type 2	1,112	Insulin Glargine U100	ejriiyjomt(pnbmucvgsq) = tlflpmpxvb fhjdidgrty (wkarfbsdjn )	Positive	22 Sep 2020
				Insulin Glargine U300	ejriiyjomt(pnbmucvgsq) = yvpeibvwiu fhjdidgrty (wkarfbsdjn )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis